ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shared further positive news with investors on Thursday, revealing it has signed an agreement with Nasdaq-listed Recursion Pharmaceuticals Inc for a fully funded pilot study.
Recursion is a clinical-stage 'techbio' company, which uses artificial intelligence and automation to conduct experimental biology for testing compounds of cellular disease models.
The AIM-listed liquid biopsy company said further details of the agreement are confidential.
"Whilst the study is modest in size during the pilot phase, there is the potential for larger follow-on contracts in the event of a successful pilot study," said ANGLE chief executive Andrew Newland.
"Recursion has partnerships with multiple leading large pharma companies and this agreement, ANGLE's fourth for 2024, further builds on the expansion of our large pharma services business."